1/30/2024 0 Comments Nasdaq bpmc news![]() raised its stake in shares of Blueprint Medicines by 63.4% in the 3rd quarter. acquired a new position in Blueprint Medicines during the 1st quarter valued at $36,000. Large investors have recently bought and sold shares of the stock. Hedge Funds Weigh In On Blueprint Medicines Company insiders own 3.88% of the company’s stock. ![]() In the last three months, insiders sold 42,233 shares of company stock valued at $2,666,539. The disclosure for this sale can be found here. Following the transaction, the director now owns 176,050 shares of the company’s stock, valued at $11,885,135.50. The shares were sold at an average price of $67.51, for a total transaction of $1,012,650.00. Albers sold 15,000 shares of the company’s stock in a transaction on Friday, November 24th. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Following the completion of the transaction, the insider now directly owns 25,095 shares in the company, valued at approximately $1,415,358. The shares were sold at an average price of $56.40, for a total transaction of $33,840.00. Murray sold 600 shares of the company’s stock in a transaction on Thursday, October 26th. ![]() The transaction was disclosed in a legal filing with the SEC, which is available through this link. Following the completion of the sale, the director now directly owns 176,050 shares of the company’s stock, valued at approximately $11,885,135.50. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $77.79. Three analysts have rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Finally, Oppenheimer upgraded shares of Blueprint Medicines from a “market perform” rating to an “outperform” rating and set a $85.00 target price for the company in a research note on Friday, October 27th. ![]() Wedbush reiterated an “outperform” rating and issued a $80.00 target price on shares of Blueprint Medicines in a research note on Friday, November 10th. Needham & Company LLC raised their price target on shares of Blueprint Medicines from $66.00 to $74.00 and gave the stock a “buy” rating in a report on Friday, October 27th. Morgan Stanley raised their price target on shares of Blueprint Medicines from $59.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday, October 27th. HC Wainwright restated a “buy” rating and set a $85.00 price target on shares of Blueprint Medicines in a report on Monday, December 11th. Several other analysts have also recently commented on the stock. The stock had previously closed at $87.61. Blueprint Medicines traded as high as $88.86 and last traded at $88.08, with a volume of 46117 shares traded. Wells Fargo & Company currently has an overweight rating on the stock. ( NASDAQ:BPMC – Get Free Report) reached a new 52-week high during trading on Tuesday after Wells Fargo & Company raised their price target on the stock from $86.00 to $115.00. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |